Association of CYP3A5*3 and CYP1A1*2C Polymorphism with Development of Acute Myeloid Leukemia in Egyptian Patients

Document Type : Research Articles

Authors

1 Clinical and Chemical Pathology Department, National Cancer Institute, Cairo University, Egypt

2 Medical Oncology Department, National Cancer Institute, Cairo University, Egypt

Abstract

 
Aim: Cytochrome P450 (CYP) enzyme catalyzes the phase I metabolism reaction which metabolize endogenous and exogenous DNA-reactive chemical compounds and xenobiotics which could induce genotoxicity and increase the risk for leukemia. We aimed to detect frequency of CYP3A5*3 and CYP1A1*2C polymorphisms in Egyptian acute myeloid leukemia (AML) patients and to determine role of allele’s variants as a risk factor for developing leukemia. Patients and Methods: A case-control study was conducted on seventy acute myeloid leukemia patients and thirty control subjects. Samples were analyzed for prevalence of CYP3A5*3 and CYP1A1*2C polymorphisms using PCR - restriction fragment length polymorphism method. Results: CYP3A5*3 polymorphism (3/3) and (1/3) genotype were significantly elevated in AML group compared to control group (p=0.002). However, no statistical significant differences were found between patients and control group as regard CYP1A1*2C polymorphism. Conclusion: Our results suggest that Egyptians carrying CYP3A5*3 polymorphism might have an increased risk of AML emphasizing the significance of effective phase I detoxification in carcinogenesis.

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention
Volume 18, Issue 3
March 2017
Pages 747-752

Files

History

  • Receive Date: 02 February 2017
  • Revise Date: 02 March 2017
  • Accept Date: 01 April 2017

Share

How to cite

Statistics